BioRad Introduces AntiVedolizumab Antibodies Antibodies Used to Support Research into the Treatment of Ulcerative Colitis and Crohns Disease

HERCULES Calif.–May 15 2018–BioRad Laboratories Inc. NYSE BIO and BIOb a global leader of life science research and clinical diagnostic products today announced the release of a range of antivedolizumab antibodies. Vedolizumab Entyvio...